View, browse and sort the list of CPhI North America Conference sessions and show floor programming by pass type, track, and format. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.
Alan Moore is responsible for commercial activities supporting biopharmaceutical products and advanced therapies such as cell and genetic therapies. Previously he oversaw cGMP-compliant contract manufacturing of innovative cell and gene therapies for WuXi AppTec, Inc. in WuXi’s Philadelphia-based manufacturing sites, as well as supported strategic biopharmaceutical clients. He held positions of increasing responsibility over a 16 year period at BioReliance Corp. (Microbiological Associates) leading to Director of Business Development, after previously serving as Director of the firm’s Biotechnology Services Division. He served as President of Genzyme Transgenics Washington Laboratories, and Senior Regulatory Coordinator for Genzyme Corporation supporting products such as Carticel®, Epicel®, Cerezyme® , and later as Vice President of Biopharmaceutical Development Services at Genzyme Corporation’s Rockville, MD facility which provided contract development, manufacturing and testing for biological products. Prior to joining WuXi AppTec, Mr. Moore served as Executive Vice President and Chief Business Officer at Althea Technologies (San Diego, CA), a leading provider of innovative technologies along with manufacturing and aseptic fill and finish services. Mr. Moore has presented on biopharmaceutical, cell and gene therapy development and safety to the U.S. FDA Center for Biologics Evaluation and Research, various U.S. FDA Advisory Committees, Health Protection Branch, Drugs Directorate (Canada), Therapeutic Goods Administration (Australia), Japan Health Science Council (Ministry of Health), and the U.K. Xenotransplantation Interim Regulatory Authority (UKXIRA). He has also served as a member of U.S./Japan Bilateral Forum on the Harmonization of Biotechnology Regulations (United States Department of Commerce– Predecessor to ICH), and a delegate to the International Bioindustry Forum (US/Japan/EU), The President's Council on Competitiveness for Streamlining Federal Regulation of Biotechnology Products at The White House.